Cetera Investment Advisers
CYTK icon

Cetera Investment Advisers’s Cytokinetics CYTK Stock Holding History

Cetera Investment Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
13,232
+4,583
+53% +$329K ﹤0.01% 2944
2026
Q1 		$570K Sell
8,649
-5,620
-39% -$357K ﹤0.01% 3383
2025
Q4 		$907K Sell
14,269
-2,870
-17% -$179K ﹤0.01% 2902
2025
Q3 		$942K Buy
17,139
+10,504
+158% +$433K ﹤0.01% 2822
2025
Q2 		$219K Buy
6,635
+731
+12% +$25.4K ﹤0.01% 3657
2025
Q1 		$237K Buy
5,904
+1,353
+30% +$62.2K ﹤0.01% 3468
2024
Q4 		$214K Sell
4,551
-21,484
-83% -$1.12M ﹤0.01% 3382
2024
Q3 		$1.37M Sell
26,035
-1,285
-5% -$71.6K ﹤0.01% 1879
2024
Q2 		$1.48M Buy
27,320
+15,366
+129% +$928K ﹤0.01% 1801
2024
Q1 		$838K Buy
+11,954
New +$925K ﹤0.01% 2219

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers's CYTK Position: Q2 2026 in Review

Cetera Investment Advisers increased its Cytokinetics (CYTK) stake by 53% in Q2 2026, buying an estimated $329K and bringing the position to 13,232 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

Cetera Investment Advisers first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.48M in Q2 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Cetera Investment Advisers held 13,232 shares of Cytokinetics worth $1.13M as of Q2 2026.
  • Cetera Investment Advisers bought 4,583 Cytokinetics shares in Q2 2026, an estimated $329K.
  • Cytokinetics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2944 holding.
  • Cetera Investment Advisers first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
  • Cetera Investment Advisers's Cytokinetics position peaked at $1.48M in Q2 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.